Immunology Investor Event
The Leading Immunology Brand
in Specialty Dermatology
U.S. monthly dermatologist NBRx'
5,000
Jan
2016
Apr-17
Launch
sanofi
COVID19
попривет
DUPIXENT
(dupilumab)
HumiraⓇ
CosentyxⓇ
TaltzⓇ
TremfyaⓇ
StelaraⓇ
Outstanding performance
8% AD 6Y+ biologic
eligible patient penetration²
In 2021, Germany and Japan
advanced therapy market
grew >50% in a competitive
environment
In competitive environment,
DupixentⓇ aims to be the
gold-standard and foundational
first-line systemic therapy
in moderate to severe AD
Jan
2022
1. IQVIA NPA Patient Insights, Jan'22. 2. IQVIA Custom Monthly Patient Report, Jan 22. AD: moderate to severe atopic dermatitis. All registered trademarks are owned by their
respective companies. Leading Immunology Brand in US NBRx.
19 Immunology Investor EventView entire presentation